CARTHIAE-1

N/A

Report date: 2024/12/20 15:00:00

Base Information

Drug NameCARTHIAE-1

Drug Alias NameChimeric antigen receptor T cells (Miltenyi Biotec Inc)CARTHIAE-1

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphoid

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBrazil

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesMiltenyi Biotec Inc

China Registration ClassN/A

Develop Information

Active CompaniesMiltenyi Biotec Inc

Inactive CompaniesN/A

Active IndicationsLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphoid

Inactive IndicationsN/A

Other Information

ATC CodeN/A